This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 1, 1997 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
Hospice Care and the Pharmacist |
Vol. 1 No. 1 |
11 |
Rectal and Stomal Administration of Analgesic Suppositories |
Vol. 1 No. 1 |
12 |
Omeprazole (Prilosec) in the Atypical Patient, Administration of |
Vol. 1 No. 1 |
13 |
The Ten Basic Steps in Filling a Prescription: Then and Now |
Vol. 1 No. 1 |
14 |
Aromatherapy and the Hospice Patient |
Vol. 1 No. 1 |
18 |
Aromatherapy Mood Elevation No. 1 |
Vol. 1 No. 1 |
20 |
Aromatherapy Mood Elevation No. 2 |
Vol. 1 No. 1 |
21 |
An Ancient Heritage Beckons Pharmacists |
Vol. 1 No. 1 |
22 |
ABH Hard Troche |
Vol. 1 No. 1 |
26 |
ABH Soft Troche |
Vol. 1 No. 1 |
27 |
ABH Sugar Troche |
Vol. 1 No. 1 |
27 |
Antiemetic Suppositories of the Gralla Type |
Vol. 1 No. 1 |
28 |
HDDM Hard Troche |
Vol. 1 No. 1 |
29 |
HDDM Soft Troche |
Vol. 1 No. 1 |
30 |
HDDM Sugar Troche |
Vol. 1 No. 1 |
30 |
Metoclophen Nausea Suppositories |
Vol. 1 No. 1 |
31 |
Metoclophen-Modified Nausea Suppositories |
Vol. 1 No. 1 |
31 |
Morphine Sulfate Slow-Release Suppositories |
Vol. 1 No. 1 |
32 |
Ondansetron HCl Suppositories |
Vol. 1 No. 1 |
34 |
Morphine Suppositories |
Vol. 1 No. 1 |
36 |
Scopolamine Hydrobromide 0.4-mg/0.1-mL Nasal Solution |
Vol. 1 No. 1 |
37 |
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel |
Vol. 1 No. 1 |
38 |
Suppository Displacement Factor |
Vol. 1 No. 1 |
39 |
Rule of Sixes for Filling Hard-Shell Gelatin Capsules |
Vol. 1 No. 1 |
40 |
Electronic Balance Maintenance/Calibration |
Vol. 1 No. 1 |
45 |
General Guidelines for Use of Chemicals for Prescription Compounding |
Vol. 1 No. 1 |
46 |
Compounding an Extended Stability Admixture of Paclitaxel for Long-Term Infusion |
Vol. 1 No. 1 |
49 |
Effect of Fat Emulsion and Supersaturation in Parenteral Nutrition Admixtures |
Vol. 1 No. 1 |
54 |
Stability of an Extemporaneously Formulated Levothyroxine Sodium Syrup Compounded from Commercial Tablets |
Vol. 1 No. 1 |
60 |
PostScription: The 90s Pharmacist |
Vol. 1 No. 1 |
64 |
The Decision to Compound |
Vol. 1 No. 2 |
71 |
The Compounding Pharmacist |
Vol. 1 No. 2 |
73 |
NABP Guidelines: Good Compounding Practices Applicable to State-Licensed Pharmacies |
Vol. 1 No. 2 |
75 |
The Mortar and Pestle |
Vol. 1 No. 2 |
80 |
Compounding for the Pediatric Patient |
Vol. 1 No. 2 |
84 |
Attention Deficit Hyperactivity Disorder |
Vol. 1 No. 2 |
87 |
Flavors and Flavoring |
Vol. 1 No. 2 |
90 |
Compounded Suppositories and Pharmaceutical Care |
Vol. 1 No. 2 |
93 |
Acetazolamide 25-mg/mL Oral Liquid |
Vol. 1 No. 2 |
101 |
Azathioprine 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
102 |
Flecainide Acetate 20-mg/mL Oral Liquid |
Vol. 1 No. 2 |
103 |
Methylcellulose 1% to 5% Solutions |
Vol. 1 No. 2 |
104 |
Methylcellulose Oral-Liquid Vehicles |
Vol. 1 No. 2 |
105 |
Pediatric Chewable Gummy Gel Base |
Vol. 1 No. 2 |
106 |
Pediatric Chocolate Troche Base |
Vol. 1 No. 2 |
106 |
Pediatric Chewable Gummy Gels |
Vol. 1 No. 2 |
107 |
Pediatric Chocolate Troche |
Vol. 1 No. 2 |
108 |
Nystatin Popsicles |
Vol. 1 No. 2 |
109 |
Procainamide HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
110 |
Syrup NF |
Vol. 1 No. 2 |
111 |
Tetracaine 20-mg Lollipops |
Vol. 1 No. 2 |
112 |
Tetracycline Compound Troche |
Vol. 1 No. 2 |
113 |
Xanthan Gum Suspension Vehicle (0.2% to 0.5%) |
Vol. 1 No. 2 |
114 |
Methylcellulose, Featured Excipient: |
Vol. 1 No. 2 |
115 |
Use, Standardization, Care of a pH Meter |
Vol. 1 No. 2 |
116 |
Particle Size Distribution of Propofol Injection from Ampules and Vials: The Benefits of Filitration |
Vol. 1 No. 2 |
118 |
The Compatibility of Common Respiratory Therapy Drug Combinations |
Vol. 1 No. 2 |
121 |
Stability of Vancomycin HCl in MEDICATION CASSETTE Reservoirs |
Vol. 1 No. 2 |
123 |
Quantitation of Metoprolol Tartrate and Propranolol Hydrochloride in Pharmaceutical Dosage Forms: Stability of Metoprolol in an Aqueous Mixture |
Vol. 1 No. 2 |
125 |
Stability of Allopurinol Suspension Compounded from Tablets |
Vol. 1 No. 2 |
128 |
Stability of Aminocaproic Acid Injection Admixtures in 5% Dextrose Injection and 0.9% Sodium Chloride Injection |
Vol. 1 No. 2 |
132 |
PostScription: Growing the Tree of Pharmacy |
Vol. 1 No. 2 |
136 |
The Changing Body |
Vol. 1 No. 3 |
144 |
Creative Compounding for the Geriatric Patient |
Vol. 1 No. 3 |
147 |
Drug Products and Drug Packaging for the Elderly |
Vol. 1 No. 3 |
150 |
Common Diseases of the Elderly |
Vol. 1 No. 3 |
152 |
Building a Compounding Lab: Remodeling an Existing Facility or Starting from Scratch? |
Vol. 1 No. 3 |
156 |
Patient Handouts |
Vol. 1 No. 3 |
160 |
Computer Technology in the Compounding Pharmacy, The Use of |
Vol. 1 No. 3 |
162 |
Parenteral Admixture Incompatibilities:An Introduction |
Vol. 1 No. 3 |
165 |
Physical Stability of Urea Topical Formulations |
Vol. 1 No. 3 |
168 |
Allopurinol 20-mg/mL Oral Liquid |
Vol. 1 No. 3 |
174 |
Antiemetic Injection for Cancer Chemotherapy |
Vol. 1 No. 3 |
175 |
Dipyridamole 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
176 |
Dry Skin and Massage Lotion |
Vol. 1 No. 3 |
177 |
Fentanyl and Bupivacaine Injection for Ambulatory Pump Reservoir |
Vol. 1 No. 3 |
178 |
Labetalol HCl 40-mg/mL Oral Liquid |
Vol. 1 No. 3 |
179 |
Metoprolol Tartrate 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
180 |
Piroxicam 2% in an Alcoholic Gel |
Vol. 1 No. 3 |
181 |
Progesterone 100-mg in Peanut-Oil Capsules |
Vol. 1 No. 3 |
182 |
Spironolactone 5-mg/mL with Hydrochlorothiazide 5-mg/mL Oral Liquid |
Vol. 1 No. 3 |
183 |
Spironolactone 25-mg/mL Oral Liquid |
Vol. 1 No. 3 |
184 |
Triple Estrogen 2.5-mg in Oil Capsules |
Vol. 1 No. 3 |
185 |
Triple Estrogen 2.5-mg in Lactose Capsules |
Vol. 1 No. 3 |
186 |
Triple Estrogen 2.5-mg Semisolid-Filled Hard-Gelatin Capsules |
Vol. 1 No. 3 |
187 |
Verapamil HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 3 |
188 |
Poloxamer, Featured Excipient: |
Vol. 1 No. 3 |
190 |
Calculations |
Vol. 1 No. 3 |
191 |
The Rule of Seven |
Vol. 1 No. 3 |
191 |
Pipette Calibration |
Vol. 1 No. 3 |
192 |
The Formulation Development and Stability of Spironolactone Suspension |
Vol. 1 No. 3 |
195 |
The Formulation Development and Stability of Metronidazole Suspension |
Vol. 1 No. 3 |
200 |
Metronidazole 15-mg/mL Suspension |
Vol. 1 No. 3 |
202 |
Stability of Ketorolac Tromethamine in 5% Dextrose Injection and 0.9% Sodium Chloride Injections |
Vol. 1 No. 3 |
206 |
Stability of Cefmetazole Sodium in 5% dextrose Injection and 0.9% Sodium Chloride Injection |
Vol. 1 No. 3 |
208 |
PostScription: Fat Loss: Important in Disease Management |
Vol. 1 No. 3 |
212 |
What Makes Pharmacists Different? |
Vol. 1 No. 4 |
214 |
Veterinary Compounding: A Bird's Eye View |
Vol. 1 No. 4 |
222 |
Suggested Flavors for Veterinary Medications |
Vol. 1 No. 4 |
228 |
Animal Drug Delivery Systems |
Vol. 1 No. 4 |
229 |
Compounding for Animals: The AVMA Perspective |
Vol. 1 No. 4 |
230 |
Symposium on Veterinary Compounding: A Pivotal Meeting |
Vol. 1 No. 4 |
231 |
Compounding for Veterinary Patients: Pharmaceutical, Biopharmaceutical, Pharmacokinetic and Physiologic Considerations |
Vol. 1 No. 4 |
233 |
Marketing to Veterinarians - Field Notes |
Vol. 1 No. 4 |
236 |
Compounding for Degenerative Myelopathy in the German Shepherd |
Vol. 1 No. 4 |
241 |
Case Reports: Osteomyelitis in a Young Draft Horse; Quarter Horse Gelding with Chronic Obstructive Pulmonary Disease |
Vol. 1 No. 4 |
242 |
Beclomethasone Dipropionate 1.25 mg/mL Aerosol Solution-Veterinary |
Vol. 1 No. 4 |
243 |
Antique Pill Making Tools |
Vol. 1 No. 4 |
246 |
Antifungal for Animals |
Vol. 1 No. 4 |
250 |
Canine Antiperspirant with Chlorhexidine |
Vol. 1 No. 4 |
251 |
Canine Diarrhea Capsules |
Vol. 1 No. 4 |
252 |
Canine Eye Ulceration Drops |
Vol. 1 No. 4 |
253 |
Canine Glucose Enema 60% |
Vol. 1 No. 4 |
254 |
Canine Methylpyrazole Solution for Ethylene Glycol Poisoning |
Vol. 1 No. 4 |
255 |
Canine Psyllium Hydrophilic Balls |
Vol. 1 No. 4 |
256 |
Cyclosporine Ophthalmic Drops for Animals |
Vol. 1 No. 4 |
257 |
Hair Moisturizer/Conditioner for Horses and Other Animals |
Vol. 1 No. 4 |
258 |
Kennel Cough Inhalation Solutions (Concentrated) |
Vol. 1 No. 4 |
259 |
Phenolated Glycerin Otic Solution for Animals |
Vol. 1 No. 4 |
260 |
Potassium Bromide 500-mg/mL Oral Solution for Animals |
Vol. 1 No. 4 |
261 |
Silver Sulfadiazine 1% Otic Lotion for Animals |
Vol. 1 No. 4 |
262 |
Sterile Vehicle for Mastitis Preparation for Animals |
Vol. 1 No. 4 |
263 |
Sulfur and Peruvian Balsam Ointment for Mange/Ringworm for Animals |
Vol. 1 No. 4 |
264 |
Carbopols, Featured Excipient: |
Vol. 1 No. 4 |
265 |
Calculations |
Vol. 1 No. 4 |
267 |
Monitoring Air Temperature and Humidity |
Vol. 1 No. 4 |
268 |
Atropine Overdosage with a Suppository Formulation Containing Atropine Sulfate |
Vol. 1 No. 4 |
271 |
Development of Clonidine HCl Injections for Epidural and Intrathecal Administration |
Vol. 1 No. 4 |
274 |
Stability of Bethanechol Chloride Oral Liquid Dosage Forms |
Vol. 1 No. 4 |
278 |
Stability of Ceftriaxone Sodium When Mixed with Metronidazole Injection |
Vol. 1 No. 4 |
280 |
Stability of Mitomycin Aqueous Solution When Stored in Tuberculin Syringes |
Vol. 1 No. 4 |
282 |
PostScription: Compounding: Our Heritage |
Vol. 1 No. 4 |
286 |
Home Infusion and Alternative-Site Health Care: The Big Picture |
Vol. 1 No. 5 |
294 |
Continued Growth Predicted for Home Infusion Market |
Vol. 1 No. 5 |
298 |
Drug Stability and Compatibility: Special Considerations for Home Health Care |
Vol. 1 No. 5 |
301 |
Ambulatory Infusion Pump Review |
Vol. 1 No. 5 |
306 |
The Future and the Pharmacy Technician |
Vol. 1 No. 5 |
310 |
Extemporaneous Compounding in the Hospital Pharmacy |
Vol. 1 No. 5 |
314 |
Acetylcysteine 10% Ophthalmic Solution |
Vol. 1 No. 5 |
320 |
Baclofen 10-mg/mL Oral Liquid |
Vol. 1 No. 5 |
321 |
Captopril 0.75-mg/mL Oral Liquid |
Vol. 1 No. 5 |
322 |
Diltiazem HCl 12-mg/mL Oral Suspension |
Vol. 1 No. 5 |
323 |
Doxorubicin HCl-Vincristine Sulfate Injection |
Vol. 1 No. 5 |
324 |
Fentanyl-Bupivacaine-Epinephrine for Epidural Analgesia |
Vol. 1 No. 5 |
325 |
Granisetron HCl-Dexamethasone Sodium Phosphate Injection |
Vol. 1 No. 5 |
326 |
Hydromorphone HCl 10-, 25-, and 50-mg/mL Injections |
Vol. 1 No. 5 |
327 |
Metoclopramide-Lorazepam-Mannitol-Prochlorperazine Antiemetic Injection |
Vol. 1 No. 5 |
328 |
Metolazone 1-mg/mL Oral Suspension |
Vol. 1 No. 5 |
329 |
Morphine Sulfate-Bupivacaine HCl Injection |
Vol. 1 No. 5 |
330 |
Morphine Sulfate 10-, 25-, and 50-mg/mL Injections (Preservative Free) |
Vol. 1 No. 5 |
331 |
Ondansetron HCl-Dexamethasone Sodium Phosphate Injection |
Vol. 1 No. 5 |
332 |
Ondansetron HCl-Doxorubicin HCl-Dacarbazine Injection |
Vol. 1 No. 5 |
333 |
Ondansetron HCl-Doxorubicin Sulfate-Vincristine Sulfate Injection (2 concentrations) |
Vol. 1 No. 5 |
334 |
Tropicamide-Hydroxyamphetamine Hydrobromide Ophthalmic Solution |
Vol. 1 No. 5 |
335 |
Benzalkonium Chloride, Featured Excipient: |
Vol. 1 No. 5 |
336 |
Assaying Progesterone in Extemporaneously Prepared Suppositories |
Vol. 1 No. 5 |
339 |
Paper-Folding Techniques for Compounded, Individualized Powder Dosage Forms |
Vol. 1 No. 5 |
340 |
Calculations |
Vol. 1 No. 5 |
343 |
Maintenance of Horizontal Laminar Airflow Hood |
Vol. 1 No. 5 |
344 |
Chemical Stability of Amiodarone Hydrochloride in Intravenous Fluids |
Vol. 1 No. 5 |
347 |
Some Quality Control Tests on Chromium Picolinate in Solid Dosage Forms |
Vol. 1 No. 5 |
349 |
The Stability of Lisinopril as an Extemporaneous Syrup |
Vol. 1 No. 5 |
352 |
Compatibility of Vancomycin Hydrochloride and Famotidine in 5% Dextrose Injection |
Vol. 1 No. 5 |
354 |
Compatibility of Warfarin Sodium with Selected Drugs and Large-Volume Parenteral Solutions |
Vol. 1 No. 5 |
356 |
PostScription: Should Just Any Pharmacist Compound? |
Vol. 1 No. 5 |
362 |
Ambulatory Care and the Compounding Pharmacist |
Vol. 1 No. 6 |
374 |
Profile of a Practice - Compounding and Pharmaceutical Care Programs Increase Traffic |
Vol. 1 No. 6 |
376 |
Ambulatory Care Medicine: Definition and Scope of Service |
Vol. 1 No. 6 |
377 |
Compounding for Diabetic Patients:An Interview with Paul Lofholm, PharmD |
Vol. 1 No. 6 |
381 |
Compounding Pharmacists Play a Vital Role in AIDS Treatment |
Vol. 1 No. 6 |
386 |
Treating Patients with Asthma |
Vol. 1 No. 6 |
389 |
Antique Suppository Making Tools |
Vol. 1 No. 6 |
392 |
Basic Statistical Concepts for Evaluating Pharmaceutical Compounding Literature: Part 1.Statistics for Continuous Data and Stability Studies |
Vol. 1 No. 6 |
395 |
FDA and the Practice of Pharmacy: Regulatory Aspects of Compounding |
Vol. 1 No. 6 |
399 |
Acyclovir Lip Balm |
Vol. 1 No. 6 |
405 |
Acyclovir Stick with Sunscreen |
Vol. 1 No. 6 |
406 |
Aspirin in Chloroform (Chloroform Banned in US) |
Vol. 1 No. 6 |
407 |
Bismuth Iodoform Paraffin Paste (BIPP) |
Vol. 1 No. 6 |
408 |
Curcumin Ointment |
Vol. 1 No. 6 |
409 |
Dexamethasone and Lidocaine Solution for Iontophoresis |
Vol. 1 No. 6 |
410 |
Estriol Solution for Iontophoresis for Acne Scars |
Vol. 1 No. 6 |
411 |
Fluconazole 200-mg Suppositories |
Vol. 1 No. 6 |
412 |
Fluconazole 2% Shampoo |
Vol. 1 No. 6 |
413 |
Ketoconazole 20-mg/mL Oral Liquid |
Vol. 1 No. 6 |
414 |
Ketorolac Solution for Iontophoresis |
Vol. 1 No. 6 |
415 |
Lidocaine HCl 2% Solution for Iontophoresis |
Vol. 1 No. 6 |
416 |
Morphine 10-mg Troches |
Vol. 1 No. 6 |
417 |
Vancomycin Gel (Vancomycin Paste, Vanc Paste) |
Vol. 1 No. 6 |
418 |
Wound Care Mixture |
Vol. 1 No. 6 |
419 |
Iontophoresis Devices: Clinical Applications for Topical Delivery |
Vol. 1 No. 6 |
420 |
Calculations |
Vol. 1 No. 6 |
425 |
Water, Featured Excipient: |
Vol. 1 No. 6 |
426 |
Laudanum and Paregoric: History and Compounding Considerations |
Vol. 1 No. 6 |
428 |
Origin of Laudanum and Paregoric |
Vol. 1 No. 6 |
428 |
Cleaning, Inspecting and Flow-Accuracy Testing of Ambulatory Pumps |
Vol. 1 No. 6 |
430 |
Stability of Two Concentrations of Heparin Sodium Prefilled in CADD-Micro Pump Syringes |
Vol. 1 No. 6 |
433 |
Stability of Cefepime Hydrochloride Dextrose in 5% Dextrose Injection and 0.9% Sodium Chloride Injection |
Vol. 1 No. 6 |
435 |
Short-Term Stability of Atenolol in Oral Liquid Formulations |
Vol. 1 No. 6 |
437 |
Stability of Clonazepam Suspension in HSC Vehicle |
Vol. 1 No. 6 |
440 |
PostScription: Issues for TPN Pharmacists |
Vol. 1 No. 6 |
444 |